Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Platinum-Resistant Lung Small Cell Carcinoma × PM 01183 × 90 days × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Small Cell Lung Carcinoma 10 Neoplasms 3 Sarcoma, Ewing 2 Desmoplastic Small Round Cell Tumor 2 Sarcoma 1 Platinum-Resistant Lung Small Cell Carcinoma 1 Ovarian Neoplasms 1 Leiomyosarcoma 1

Interventions

durvalumab 1 PM 01183 1 Immunoglobulin G 1 Disulfides 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04607954 2026-01-06

Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer

Mayo Clinic

Phase 2 Active not recruiting

Platinum-Resistant Lung Small Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡